AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05632432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI)
Description: To assess detailed cardiac structure (i.e. interstitial fibrosis) and function both preoperatively and at 6-month follow-up postoperatively.
Study NCT05632432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom-scaling
Description: Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
Study NCT05632432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom-scaling
Description: Standardised evaluation of IHD and HF-related angina pectoris (CCS) and dyspnea (NYHA) and life quality (RAND36) pre- and postoperatively (at both 3- and 6-month follow-up).
Study NCT05632432 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute walking test (6MWT)
Description: Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
Study NCT05632432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6MWT)
Description: Standardised assessment of physcial capacity pre- and postoperatively (at 6-month follow-up)
Study NCT05632432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling (NT-proBNP)
Description: Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
Study NCT05632432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling (NT-proBNP)
Description: Collection of a blood sample measurement of NT-proBNP by an accredited hospital laboratory pre- and postoperatively (at both 3- and 6-month follow-up).
Study NCT05632432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echocardiography
Description: Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
Study NCT05632432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Description: Performed by the perfusion-anesthesiologist at the beginning of the CABG surgery to evaluate both LAA and RAA for blood flow velocities, anatomy, possible sludge and thrombus.
Study NCT05632432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epicardial collagen-based patch transplantation
Description: Epicardial transplantation of the collaged-based patch material without the AAMs onto the epicardium of the scarred myocardium at the end of CABG surgery.
Study NCT04222959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls Invest Intervention
Description: App-based trainings: The first 2 modules cover gender and cultural norms related to girls' social and economic empowerment, increasing girls' recognition of the importance of financial literacy and independence. The last 3 modules cover finance, educational loans, and employment.~Savings account: Participants receive $100 deposited into a savings account we set up for them, conditional upon completion of app-based trainings.
Study NCT04889209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.211
Description: Lipid nanoparticle (LNP) dispersion containing 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the B.1.351 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273. mRNA-1273.211 (0.2 mg/mL) will be administered in 0.5 mL doses (100 mcg/0.5 mL).
Study NCT04889209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.222
Description: Formulated in the same way as the mRNA-1273 vaccine but contains 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273.
Study NCT04889209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/M1
Description: SARS-CoV-2 rS Drug Substance containing the prototype Wuhan is formulated with saponin-based Matrix-M adjuvant in a buffer of 25 mM sodium phosphate (pH 7.2), 300 mM sodium chloride, and 0.01% (weight per volume \[w/v\]) polysorbate 80. NVX-Co-V2373 will be administered in 0.5 mL dose (5 mcg Prototype SARS-CoV-2 rS with 50 mcg Matrix-M adjuvant)
Study NCT06410157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily practice
Description: Participants will be asked to undergo daily mindfulness practice while regulating (either increase or decrease) heart rate oscillation.
Study NCT05307406 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimental
Description: Participants will receive a single IV infusion in a double blind manner
Study NCT05307406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Participants will receive a single IV infusion in a double blind manner
Study NCT06505460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study NCT06505460 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study NCT06518304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GentleWave
Description: GentleWave System employs a degassing process that removes dissolved gases from the solution. This optimization prevents the vapor-lock effect and ensures effective energy transmission through the root canal. As the solution enters the pulp chamber, hydrodynamic cavitation occurs, creating microbubbles that implode and generate sound waves across a broad frequency spectrum
Study NCT06518304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Protocol
Description: Delivers irrigants (NaOCl, EDTA) through a needle-syringe system, often fails to reach the entire working length. This inadequacy can result in residual bacteria and necrotic tissue, potentially compromising treatment efficacy and increasing the risk of treatment failure.
Study NCT06469801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperfine
Description: Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO. Patients will undergo imaging within 24 hours of ECMO initiation/cannulation. Patients that remain on ECMO will have repeat imaging at 72-120 hours of ECMO therapy and again weekly for the duration of their ECMO course. Patients will also undergo a portable MRI within 24 hours of clinical head imaging, if applicable.
Study NCT04767321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 gel, 3% w/w
Description: LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
Study NCT04767321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
Study NCT06311357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Ensure 6 scoops dietary supplement powder in 250 ml of water, 2 drinks per days for 12 weeks.
Study NCT06304857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg tablet q.d
Study NCT06304857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet matching dapagliflozin 10 mg q.d
Study NCT05506943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-009
Description: IV infusion on day 1 and 14 of every 28 day cycle
Study NCT05506943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion on day 1, 8, and 15 of every 28 day cycle
Study NCT05506943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion on day 1, 8, and 15 of every 28 day cycle
Study NCT06553521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MyHEARTSMAP Youth Self-assessment Tool (At Admission)
Description: MyHEARTSMAP is a validated self-assessment tool for pediatric populations, demonstrating high sensitivity and specificity for identifying psychosocial concerns. Adapted from HEARTSMAP, it allows self- and proxy-reporting across 10 well-being domains, providing personalized recommendations. Currently, the clinician-reported HEARTSMAP is the standard of care at BC Children's Hospital ED for the initial assessment of youth with primary psychiatric concerns
Study NCT05968833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iParent2Parent Program
Description: iParent2Parent is an online peer support mentorship program that is based on the iPeer2Peer online peer support mentorship program, which has been established in multiple chronic disease populations as a self-management intervention, including in chronic pain and juvenile idiopathic arthritis populations. The iParent2Parent program connect parents one-to-one with other parents of pediatric kidney transplant recipients who are trained to offer vital peer support and mentorship.
Study NCT06318624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilisation with Movement and Taping
Description: For MWM for the talocrural joint, the hemiparetic side of the participant is positioned in a standing position on a stool. A non-elastic belt is passed behind the patient's distal tibia and secured around the therapist's pelvis. The patient is asked to perform active knee flexion and ankle dorsiflexion with weight on the hemiparetic side. Meanwhile, the therapist performs forward sliding of the tibia with the help of the belt. For 10 seconds active and painless sliding takes place and then return to the starting position. This application is applied as 10 repetitions, 6 sets, and 1 minute rest between sets. Following the MWM application, Mulligan talus stabilization taping is performed. For this taping, the participants' ankles are placed on a stool at a height of 30 cm and their feet are placed in the dorsiflexion position. The therapist starts taping from the plantar surface of the calcaneus using rigid tape and will wrap and stabilize the talus.
Study NCT06318624 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: During joint mobilization with movement, the therapist will stabilize the ankle while performing knee flexion and ankle dorsiflexion by actively moving the center of mass to the affected side, but the shear force required to slide the tibia forward with the belt will not be given. Placebo taping following the application will be applied in such a way that there is no stabilization effect without tension between the same start and end points.
Study NCT06553677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunneled coronal advanced flap with connective tissue graft
Description: Tunneled coronal advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites.
Study NCT06553677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap with connective tissue graft
Description: Coronally advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites
Study NCT05691634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patient with a tatoo will perform an MRI. The possible symptoms during the MRI or after MRI will then be described (duration, type,...).
Study NCT05691634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Likert scale questionnaire
Description: The patient will appreciate his feeling after MRI on a Likert scale (from 1 to 5)
Study NCT05201274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin sequential therapy
Description: A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003.
Study NCT05850091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Pharmacotherapy for reduction in LDL cholesterol level
Study NCT05850091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Pharmacotherapy for inflammation inhibition
Study NCT05850091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with sugar pill that mimics active study drugs
Study NCT05850091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule with sugar pill that mimics active study drugs
Study NCT05201274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
Study NCT05272046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per-oral Endoscopic Myotomy
Description: Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
Study NCT05272046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Per-oral Endoscopic Myotomy
Description: Therapeutic endoscopy procedure by means of electrocautery surgical tools for treatment of various esophageal conditions such as achalasia or spastic esophageal disorders.
Study NCT05272046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Speedboat (Bipolar electrocautery knife)
Description: Use of Creo Medical's Speedboat RS2 knife and generator in performing the POEM procedure for patients presenting with an esophageal motility disorder.
Study NCT04821336 — intervention group
Intervention type: OTHER
Intervention: Metabolites dosage
Description: On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand.~The investigators will compare the rate of deregulation between sane and malignant ones.
Study NCT05664100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-345
Description: Single intratympanic injection of FX-345
Study NCT05664100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study NCT04689425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood mononuclear cell gel（MNC）
Description: Local wound treatment by combination of PRP and MNC, once;
Study NCT04689425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The platelet rich plasma（PRP）
Description: Local wound treatment by PRP alone, once.
Study NCT04689425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The platelet rich plasma（PRP）
Description: Local wound treatment by PRP alone, once.
Study NCT06285929 — intervention group
Intervention type: OTHER
Intervention: ACS CARES Student Navigation
Description: Student volunteers providing navigation support to patients, families and caregivers with a cancer diagnosis through an SDOH assessment.
Study NCT05424718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile
Description: Mobile technology to deliver HIV prevention information specifically developed for at-risk young men that have sex with men (YMSM).
Study NCT05281926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: IT Poly-ICLC injection (1.0 mg) at Day 1 of weeks 0, 1 and 2. IM Poly-ICLC (20 μg/Kg) at Day 1 and Day 3 of weeks 3, 4, 5 and 6.
Study NCT05580952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement system
Study NCT05436704 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-FNB
Description: EUS-FNB
Study NCT05077423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD33*CD3 BsAb
Description: CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
Study NCT06245031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensory Stimulation System (GS120) - Active
Description: Sensory Stimulation System (GS120) - Active settings
Study NCT04614558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb).
Study NCT05559346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic exercises
Description: Diaphragm exercises will be applied to the research group in addition to conventional rehabilitation.The content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control. In addition to conventional rehabilitation, manual diaphragmatic relaxation exercises and diaphragmatic breathing exercises will be applied to the children in the research group two days a week.
Study NCT05559346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: The control group will only be taken to the conventional rehabilitation program. e content of the individualized conventional rehabilitation program consists of passive stretching exercises, strengthening exercises to antagonists of spastic muscles and exercises aimed at improving weight transfer, balance and correction reactions, and postural control.
Study NCT05654012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: Grey Matter Volume (T1) Resting state BOLD
Study NCT05654012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermal Stimuli
Description: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
Study NCT05654012 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pressure stimuli
Description: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
Study NCT05654012 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pain ratings
Description: Pain intensity and pain unpleasantness ratings will be assessed by numerical rating scale (ranging from 0- no pain/unpleasantness to- 10 or 100 the most intense/unpleasantness pain imaginable) and by mechanical and computerized visual analog scales (VAS which ranges between ''no pain sensation'' and ''most intense pain imaginable'').
Study NCT05540457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Non-InvasiveBlood Pressure Monitor
Description: Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis.
Study NCT05654012 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pressure pain thresholds (PPT)
Description: Pressure will be increased continually and participants will be instructed to press a button the first moment they feel pain from the pressure stimulus.
Study NCT04823208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC
Study NCT04823208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05654012 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conditioned pain modulation (CPM) efficiency
Description: The CPM paradigm assesses endogenous inhibitory pain modulation efficiency related to spatial filtering of nociceptive information.
Study NCT05549544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing
Description: Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
Study NCT05632458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.